Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
75.6M
-
Shares change
-
+6.26M
-
Total reported value, excl. options
-
$107M
-
Value change
-
+$8.58M
-
Put/Call ratio
-
0.1
-
Number of buys
-
50
-
Number of sells
-
-49
-
Price
-
$1.41
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q2 2023
140 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q2 2023.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.6M shares
of 229M outstanding shares and own 33.04% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34.9M shares), BlackRock Inc. (9.01M shares), VANGUARD GROUP INC (7.16M shares), Defender Capital, LLC. (5.11M shares), GEODE CAPITAL MANAGEMENT, LLC (2.42M shares), Laurion Capital Management LP (1.97M shares), STATE STREET CORP (1.94M shares), Prescott General Partners LLC (1.85M shares), RAFFLES ASSOCIATES LP (1.6M shares), and NORTHERN TRUST CORP (1.1M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.